Information  X 
Enter a valid email address

Redx Pharma plc (REDX)

  Print      Mail a friend

Wednesday 20 May, 2020

Redx Pharma plc

Change of Adviser

RNS Number : 3816N
Redx Pharma plc
20 May 2020
 

20 May 2020

 

Redx Pharma plc

("Redx" or "the Company")

 

Change of Adviser

 

The Company announces that SPARK Advisory Partners Limited has been appointed as the Company's nominated adviser with immediate effect.

 

 

For further information, please contact:

 

 

 

Redx Pharma Plc 

T: +44 1625 469 918

Iain Ross, Chairman

Lisa Anson, Chief Executive

 

 

 

SPARK Advisory Partners Limited (Nominated Adviser)

 T: +44 203 368 3550

Matt Davis/Andrew Emmott

 

 

 

WG Partners LLP (Broker)

T: +44 20 3705 9330

Claes Spång/Chris Lee/David Wilson

 

 

 

FTI Consulting

T: +44 20 3727 1000

Simon Conway/Ciara Martin

 

 

 

 

 

About Redx Pharma Plc

 

Redx is a UK based biotechnology company whose shares are traded on AIM (AIM:REDX). Redx's vision is to become a leading biotech focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases.

 

If you would like to sign up to regular alerts from Redx Pharma, please follow this link https://www.redxpharma.com/investors/email-alerts/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
APPSFDFDUESSEEI

a d v e r t i s e m e n t